Cancer Immunotherapy Today: Maximizing Patient Outcomes

May 31 from 12:30 PM-5:00 PM and June 1 from 7:30 AM-11:00 AM
McCormick Place, Room S100bc

Seminar Description

This seminar enables clinical oncologists, nurses, pharmacists, and the entire medical team to effectively offer their patients additional treatment options through immunotherapy. Advances in cancer immunotherapy research are rapidly emerging, with an increasing rate of new approvals for the routine clinical use of immunotherapy agents in the clinic across a variety of cancers. The pace of progress in the field necessitates the continuing education of oncology clinicians to enable them to provide the most up-to-date and comprehensive immunotherapy-based treatment options to their patients. In addition, oncologists, nurses and pharmacists with basic knowledge related to utilizing immunotherapy in clinical practice continue to be challenged by issues related to patient selection and toxicity management. This seminar will be co-sponsored with the Society for Immunotherapy of Cancer (SITC).

Go to interact.asco.org/immuno to view session slides on your personal device in real time, take notes on slides, pose questions to faculty, and participate in audience polling. Link will be live when the session begins on Thursday, May 31.

Seminar Agenda

Note: Session faculty will be added to the agenda below as presenters are confirmed.

Day 1: Thursday, May 31, 2018: 12:30 PM - 5:00 PM

12:30 PM - 1:00 PM Lunch
1:00 PM - 1:25 PM

Session 1: Basic Principles of Immunotherapy

 

Mario Sznol, MD
Yale School of Medicine
Immunotherapy Basics

 

Panel Question and Answer

1:25 PM - 2:55 PM

Session 2: Integrating Immunotherapy Into Clinical Practice—Changes Over the Past Year (Part 1)
Leisha Emens, MD, PhD—Chair

The Johns Hopkins University

Neiyer A. Rizvi, MD—Chair
Columbia University Medical Center

 

Michael A. Postow, MD
Memorial Sloan Kettering Cancer Center
Melanoma and Other Skin Cancers

 

Question and Answer

 

Naiyer A. Rizvi, MD
Columbia University Medical Center
Lung Cancer

 

Question and Answer

 

Leisha A. Emens, MD, PhD
The Johns Hopkins University
Breast and Gynecologic Cancers

 

Question and Answer

2:55 PM - 3:10 PM Break
3:10 PM - 5:00 PM

Session 3: Integrating Immunotherapy Into Clinical Practice—Changes Over the Past Year (Part 2)
 

Doreen Higgins, RN, BSN, CCRP—Chair
University of Washington

Alexander I. Spira, MD, PhD, FACP—Chair
Virginia Cancer Specialists Research Institute and Oncology Research

 

Michael Morse, MD
Duke University School of Medicine
Gastrointestinal Cancers

 

Question and Answer

 

Neeraj Agarwal, MD
Huntsman Cancer Institute at the University of Utah
Genitourinary Cancers

 

Question and Answer

 

Robert L. Ferris, MD, PhD, FACS
University of Pittsburgh Medical Center and University of Pittsburgh Cancer Institute
Head and Neck Cancers

 

Question and Answer

 

Alexander I. Spira, MD, PhD, FACP
Virginia Cancer Specialists Research Institute and Oncology Research
The Impact of Immunotherapy On A Community Practice

Question and Answer

 

Day 2: Friday, June 1, 2018: 7:00 AM - 11:00 AM

7:00 AM - 7:30 AM Breakfast
7:30 AM - 8:15 AM

Session 4: Hematologic Malignancies and CAR-T Cell Therapy

 

Mario Sznol, MD—Chair
Yale School of Medicine

 

John Timmerman, MD—Chair
University of California, Los Angeles
Hematologic Malignancies

 

Kevin J. Curran, MD
Memorial Sloan Kettering Cancer Center
Clinical Application of Cell Therapies: Mechanism of Action, Efficacy, and Patient Selection

 

Panel Question and Answer

8:15 AM - 8:30 AM Break
8:30 AM - 10:30 AM

Session 5: Managing Immune-Related Adverse Events—The Challenge to Maximize the Risk/Benefit Ratio

*A case-based panel discussion

Mario Sznol, MD—Chair
Yale School of Medicine

 

Ravi A. Madan, MD—Chair
National Cancer Institute

 

Krista Rubin, APRN-BC
Massachusetts General Hospital
Nurse Perspective

 

Joachim M. Baehring, MD
Yale School of Medicine
Neurologist Perspective

 

Jaydira Del Rivero, MD
National Cancer Institute
Endocrinologist Perspective

 

Elizabeth J. Shpall, MD
The University of Texas MD Anderson Cancer Center
Cell Therapist/Benign Hematologist Perspective

10:30 AM - 11:00 AM

Session 6: The Future of Immunotherapy—Novel Agents in Clinical Trials

 

Ravi A. Madan, MD—Chair
National Cancer Institute

 

James Gulley, MD, PhD
National Cancer Institute
New Agents in Clinical Trials: Significant Phase I-III Clinical Trials

 

Panel Question and Answer

 

Seminar Committee

View Seminar Committee Disclosures

Leisha Emens, MD, PhD​ (Co-Chair)​
Johns Hopkins University

Mario Sznol, MD (Co-Chair)​
Yale School of Medicine

Marc S. Ernstoff, MD
Roswell Park Cancer Institute

Doreen Higgins, RN, BSN, CCRP
University of Washington

Ravi Madan, MD
National Cancer Institute/National Institute of Health

Lowell E. Schnipper, MD, FASCO
Beth Israel Deaconess Medical Center

Eleni Yeatras, RPh, BCOP
U.S. Oncology Research

Accreditation 

 "Jointly Accredited Provider, Interprofessional Continuing Education"

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Society of Clinical Oncology Designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Credit Designation Statement - Nurses 

The maximum number of hours awarded for this CE activity is 7.0 contact hours. 

ACPE Credit Designation Statement - Pharmacists

This activity has been approved for 7.0 contact hours (.7 CEUs) under the ACPE universal activity number JA0000152-0000-18-039-L01-P.

AAPA/NCCPA Credit Designation Statement - Physician Assistants

Physician Assistants may claim a maximum of 7.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. 

All non-physician attendees are welcome to submit a request for a Certificate of Participation, which may enable non-physicians to apply their meeting participation toward re-licensure. Please note, however, that all final decisions regarding certificate acceptance will be made by the licensing organization to which the certificate is submitted. 

Target Audience

The 2018 Cancer Immunotherapy Today: Maximizing Patient Outcomes Seminar is designed for the cancer care team; credit is offered for physicians, nurses, and pharmacists, but all are encouraged to participate, as they may be able to apply for credit through their own licensing organization.

Learning Objectives

Upon participation in this activity, attendees will be able to:

  • Review key principles in immunotherapy
  • Analyze recent change in immunotherapy in melanoma and skin cancers; lung cancer; breast and gynecologic cancers; genitourinary cancers; gastrointestinal cancer; head and neck cancers; and their impact on community practice
  • Discuss hematologic malignancies and cell therapies, including mechanism of action, efficacy, and appropriate patient selection
  • Using cases, evaluate management of immune-related adverse events to maximize risk/benefit ratio, as appropriate
  • Discuss the future of immunotherapy and ongoing clinical trials to remain current with clinical research

Disclaimer/Unlabeled Usage Statement         

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions and adverse effects.

Commercial Supporters

Novartis